MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a mixed financial performance with a decline in total revenue, reduced gross margins, and increased operating expenses. The Q&A section reveals short-term revenue challenges due to inventory adjustments and macroeconomic headwinds, despite some positive signs in instrument sales and SPL programs. The lack of specific guidance and management's avoidance of details further contribute to uncertainty. Overall, these factors suggest a likely negative stock price movement over the next two weeks.
Key Financial Performance
Total Revenue $8.5 million in Q2 2025, an 18% decline year-over-year from $10.4 million in Q2 2024. The decline was attributed to lumpy milestone revenue impacting year-over-year comparisons.
Core Revenue $8.2 million in Q2 2025, an 8% increase year-over-year from $7.6 million in Q2 2024. Growth was driven by improved instrument revenue.
Instrument Revenue $2.1 million in Q2 2025, a 22% increase year-over-year from $1.8 million in Q2 2024. Growth was attributed to improved capital equipment spending environment.
License Revenue $2.6 million in Q2 2025, flat year-over-year compared to Q2 2024. Stability was maintained despite customer program consolidations.
Processing Assembly (PA) Revenue $3.1 million in Q2 2025, a 5% increase year-over-year from $3 million in Q2 2024. Growth was supported by ordering patterns impacted by the uncertain tariff environment.
SPL Program-Related Revenue $0.3 million in Q2 2025, a significant decline from $2.9 million in Q2 2024. The decrease was due to the absence of recognized milestones during the quarter.
Gross Margin 82% in Q2 2025, compared to 86% in Q2 2024. The decline was attributed to inventory provisions and SPL program-related revenue.
Operating Expenses $21.2 million in Q2 2025, a slight increase from $20.9 million in Q2 2024. The increase was due to the integration of SeQure Dx and investments in new product initiatives.
Cash, Equivalents, and Investments $165.2 million as of the end of Q2 2025, a decrease from the beginning of the year due to $7 million in purchase transaction and onetime costs associated with the acquisition of SeQure Dx.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New SPL agreements: Signed 2 new strategic platform licenses with Anocca AB and Adicet Bio, bringing the total number of SPLs to 31. These agreements will utilize MaxCyte's ExPERT platform for advanced therapies.
SeQure Dx integration: Progressed well on the integration of SeQure Dx, which offers gene editing risk assessment services. The sales pipeline has doubled compared to the start of 2025.
New platform launch: Planned launch of a new platform later in 2025, expected to contribute to top-line growth.
Asia Pacific growth: Continued growth in the Asia Pacific region, contributing to the company's global expansion.
CASGEVY progress: Vertex's CASGEVY therapy showed positive momentum with 115 patients completing cell collection and 29 completing treatment, supported by MaxCyte's platform.
Revenue guidance adjustment: Lowered 2025 core revenue guidance to $29.5M-$32.5M, down from $35M-$37M, due to external headwinds like customer program consolidations and hesitancy in capital equipment purchases.
Instrument revenue growth: Instrument revenue grew 22% year-over-year in Q2 2025, despite a challenging capital equipment spending environment.
Operating efficiency: Operating expenses decreased slightly in the first half of 2025 compared to 2024, despite absorbing SeQure Dx costs.
Focus on profitability: Positioning the company to achieve profitability without additional capital needs, supported by disciplined investments and operational efficiencies.
FDA and regulatory alignment: Aligned with FDA's focus on accelerating cell and gene therapy development timelines, which supports MaxCyte's long-term growth potential.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Decrease in Spending by Large SPL Partner: A large SPL partner customer has reduced spending due to inventory management and reorganization of manufacturing operations, impacting leases and revenue.
Customer Program Rationalization: Some customers have rationalized programs and wound down operations internally, leading to lower expectations for PA and license revenue.
Capital Equipment Purchasing Hesitancy: Customers are hesitant to purchase capital equipment due to uncertain funding and regulatory environments in cell therapy.
Core Revenue Decline: Core business revenue is expected to be flat to down 10% in 2025, with a reduction in guidance midpoint by $5 million compared to the previous plan.
Program Consolidation and Shutdowns: Four clinical programs were shut down this year, reflecting the dynamic and uncertain environment in the cell and gene therapy industry.
Revenue Variability in SPL Program-Related Revenue: SPL program-related revenue remains lumpy and unpredictable, with significant declines compared to the prior year.
Operational Headwinds at Customers: Operational challenges at customer organizations, including manufacturing reorganizations and program consolidations, are negatively impacting MaxCyte's financial outlook.
Regulatory and Funding Challenges: Uncertainty in regulatory and funding environments is creating challenges for customers, impacting their purchasing and program decisions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Core Business Revenue Guidance for 2025: MaxCyte expects core business revenue to be flat to down 10% in 2025, representing approximately $29.5 million to $32.5 million, compared to $32.5 million in 2024. This is a revision from the previous guidance of 8% to 15% growth (approximately $35 million to $37 million).
SeQure Dx Revenue Expectation: The company continues to expect at least $2 million in full-year revenue from SeQure Dx in 2025, with revenue weighted towards the second half of the year.
SPL Program-Related Revenue Guidance: MaxCyte reiterates its SPL program-related revenue guidance, expecting approximately $5 million in 2025, including revenue from pre-commercial and commercial milestones and sales-based royalties.
Future Growth Expectations: MaxCyte expects to return to growth in 2026, driven by growth in Asia Pacific, an increasing number of clinical programs utilizing its platform, and the launch of a new platform later in 2025.
Pivotal Studies and Approvals: Five clinical programs supported by MaxCyte are expected to enter pivotal studies within the next 6 to 18 months, with potential approvals and launches in 2027 and 2028.
SeQure Dx Market Potential: The addressable market for SeQure Dx is expected to encompass the entire field of modified cell and gene therapies, with significant growth potential over the coming years.
Cash Position and Profitability: MaxCyte expects to end 2025 with approximately $155 million in cash equivalents and investments, and aims to achieve profitability without additional capital needs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the impact of the reorganization of manufacturing operations for the company's largest customer?
A:The reorganization was a short-term consolidation of manufacturing and will not impact future licensing revenue. The company has visibility into the customer's plans and does not anticipate further major changes to manufacturing operations.
Q:Will there be less instrument and license revenue due to inventory adjustments by the largest customer?
A:Yes, in the short term, there will be less instrument and license revenue as the customer works through inventory.
Q:What is the company's approach to operating expenses and profitability?
A:The company aims to be profitable in the foreseeable future and is focused on finding efficiencies. Despite absorbing expenses from the SeQure Dx acquisition, operating expenses are slightly lower than last year, demonstrating diligence in cost management.
Q:How should quarterly cadence from Q3 to Q4 be contemplated given the updated guidance?
A:The company expects a slight weighting towards Q4 in terms of the midpoint of the revised range, with variability depending on Q4 performance.
Q:What is the outlook for instrument sales and customer sentiment in the cell and gene therapy market?
A:Instrument sales were up 22% year-over-year, driven by lower-priced systems. Short-term headwinds like NIH funding concerns are dissipating, and the company is seeing strong performance in Asia Pacific. The strategy focuses on early customer engagement and scaling up with differentiated systems.
Q:What is the status of SPL partnerships and the focus of advancing programs?
A:The company is seeing a shift towards allogeneic therapies, which aligns well with its systems. Programs like CRISPR/CTX112 and others are advancing, and the company continues to sign 3-5 SPLs annually, maintaining a robust pipeline despite occasional customer shifts.
Q:Did PA revenue benefit from a pull-forward ahead of tariffs, and what is the expected impact?
A:Yes, there was a single order from a distributor ahead of tariffs, but it is not expected to have a material impact on future revenue.
Q:Are SPL customers affected by macro headwinds, and what is the impact on the pipeline?
A:Some SPL customers have shifted focus or gone in vivo, but the pipeline remains strong with 3-5 new SPLs signed annually. The company has 18 clinical programs and 5 moving into pivotal stages, indicating resilience despite short-term impacts.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the size of the benefit from the pull-forward ahead of tariffs and the exact breakdown of core revenue between instruments and PAs. Additionally, they did not disclose details about one undisclosed SPL program or provide clarity on the exact impact of macro headwinds on the SPL pipeline.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AB number
ATCs
Anocca AB
FDA
Hospital
PA program
Research Division
SPL program
SeQure
acquisition
agency
belief industry
cancer
core SPL
customer program
deck
focus MaxCyte
gene risk
initiation cell
journey Vertex
license
model SPLs
month decrease
network
platform manufacturing
platform support
profitability capital
program clinic
program line
program platform
program study
purchase
reduction
regulator
risk assessment
royalty milestone
service
MXCT Transcript
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call presents a mixed picture: strong cash position and reduced expenses are positives, but declining gross margins and lack of specific guidance for SPL milestones are concerns. The Q&A highlights cautious optimism regarding future growth and partnerships, but uncertainties about revenue contributions persist. The company's strategic focus on expanding product offerings and technological capabilities aligns with positive market trends. However, the absence of immediate catalysts and management's reluctance to provide detailed guidance suggest a neutral stock price movement over the next two weeks.
MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript
Positive3-25
The company's strong revenue growth, improved gross margin, and reduced net loss indicate positive financial performance. The optimistic revenue expectations and margin projections for 2026 further enhance the outlook. Although operational updates and risks were not discussed, the focus on product expansion and market recovery in biotech are promising. The absence of shareholder return details is a minor concern. Overall, the positive financial metrics and strategic initiatives suggest a likely positive stock price movement in the near term.
MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reflects a mixed outlook. Financial performance shows stable gross margins but a decline in non-GAAP adjusted margins. The Q&A highlights positive developments in SeQure's ramp-up and SPL pipeline, but there's a cautious approach due to challenging biotech funding and M&A environment. The guidance for 2025 is weak, but there's optimism for 2026 growth. The lack of guidance on CASGEVY and revenue shifts raises concerns. Overall, the sentiment is neutral due to balanced positive and negative factors without a strong catalyst for significant stock movement.
MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call summary indicates a mixed financial performance with a decline in total revenue, reduced gross margins, and increased operating expenses. The Q&A section reveals short-term revenue challenges due to inventory adjustments and macroeconomic headwinds, despite some positive signs in instrument sales and SPL programs. The lack of specific guidance and management's avoidance of details further contribute to uncertainty. Overall, these factors suggest a likely negative stock price movement over the next two weeks.
MXCT Slides
MXCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
